Neurodevelopment at 5.5 Years of Age in Children Who Received Infant Formula With Enriched Protein Fractions

Neurodevelopment at 5.5 Years of Age in Children Who Received Infant Formula With Enriched Protein Fractions

This is a follow-up study of a multi-center, double-blind, randomized, controlled, parallel-designed, prospective trial and is intended to evaluate neurodevelopment at 5.5 years of age and health outcomes through 5.5 years of age in participants who received one of two staged study formulas through one year of age.

Inclusion Criteria:

• Participant who previously consumed study formula through one year of age in MJN Project 6027
• 5.5 years of age (i.e. when child turns 5 years and 6 months old ± 2 months) at Visit 1
• Signed informed consent obtained for child's participation in the study

Exclusion Criteria:

• No exclusion criteria